Association of serum TRAIL level with coronary artery disease

Thrombosis Research

Volumn 125, Issue 4, 2010, Pages 322-325

  Mori, Katsuhito ^a   Ikari, Yuji ^b   Jono, Shuichi ^a   Shioi, Atsushi ^a   Ishimura, Eiji ^a   Emoto, Masanori ^a   Inaba, Masaaki ^a   Hara, Kazuhiro ^b   Nishizawa, Yoshiki ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b MITSUI MEMORIAL HOSPITAL   (Japan)

Author keywords

Atherosclerosis; Coronary artery disease; TRAIL

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; ISOSORBIDE DINITRATE; SULFONYLUREA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ADULT; ANGINA PECTORIS; ANGIOCARDIOGRAPHY; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

APOPTOSIS; BIOLOGICAL MARKERS; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; CORONARY DISEASE; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; LIGANDS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77949571279     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2009.11.024     Document Type: Article

References (27)

1. Wang S. The promise of cancer therapeutics targeting the TNF-related apoptosis-inducing ligand and TRAIL receptor pathway. Oncogene 27 (2008) 6207-6215
2. Johnstone R.W., Frew A.J., and Smyth M.J. The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat Rev Cancer 8 (2008) 782-798
3. Libby P. Inflammation in atherosclerosis. Nature 420 (2002) 868-874
4. Corallini F., Rimondi E., and Secchiero P. TRAIL and osteoprotegerin: a role in endothelial physiopathology?. Front Biosci 13 (2008) 135-147
5. Martin-Ventura J.L., Munoz-Garcia B., Egido J., and Blanco-Colio L.M. Trail and vascular injury. Front Biosci 12 (2007) 3656-3667
6. Kavurma M.M., and Bennett M.R. Expression, regulation and function of trail in atherosclerosis. Biochem Pharmacol 75 (2008) 1441-1450
7. Schoppet M., Al-Fakhri N., Franke F.E., Katz N., Barth P.J., Maisch B., et al. Localization of osteoprotegerin, tumor necrosis factor-related apoptosis-inducing ligand, and receptor activator of nuclear factor-kappaB ligand in Monckeberg's sclerosis and atherosclerosis. J Clin Endocrinol Metab 89 (2004) 4104-4112
8. Li J.H., Kirkiles-Smith N.C., McNiff J.M., and Pober J.S. TRAIL induces apoptosis and inflammatory gene expression in human endothelial cells. J Immunol 171 (2003) 1526-1533
9. Alladina S.J., Song J.H., Davidge S.T., Hao C., and Easton A.S. TRAIL-induced apoptosis in human vascular endothelium is regulated by phosphatidylinositol 3-kinase/Akt through the short form of cellular FLIP and Bcl-2. J Vasc Res 42 (2005) 337-347
10. Sato K., Niessner A., Kopecky S.L., Frye R.L., Goronzy J.J., and Weyand C.M. TRAIL-expressing T cells induce apoptosis of vascular smooth muscle cells in the atherosclerotic plaque. J Exp Med 203 (2006) 239-250
11. Janssen E.M., Droin N.M., Lemmens E.E., Pinkoski M.J., Bensinger S.J., Ehst B.D., et al. CD4+ T-cell help controls CD8+ T-cell memory via TRAIL-mediated activation-induced cell death. Nature 434 (2005) 88-93
12. Kaplan M.J., Ray D., Mo R.R., Yung R.L., and Richardson B.C. TRAIL (Apo2 ligand) and TWEAK (Apo3 ligand) mediate CD4+ T cell killing of antigen-presenting macrophages. J Immunol 164 (2000) 2897-2904
13. Secchiero P., Gonelli A., Carnevale E., Milani D., Pandolfi A., Zella D., et al. TRAIL promotes the survival and proliferation of primary human vascular endothelial cells by activating the Akt and ERK pathways. Circulation 107 (2003) 2250-2256
14. Secchiero P., Zerbinati C., Rimondi E., Corallini F., Milani D., Grill V., et al. TRAIL promotes the survival, migration and proliferation of vascular smooth muscle cells. Cell Mol Life Sci 61 (2004) 1965-1974
15. Kavurma M.M., Schoppet M., Bobryshev Y.V., Khachigian L.M., and Bennett M.R. TRAIL stimulates proliferation of vascular smooth muscle cells via activation of NF-kappaB and induction of insulin-like growth factor-1 receptor. J Biol Chem 283 (2008) 7754-7762
16. Zauli G., Pandolfi A., Gonelli A., Di Pietro R., Guarnieri S., Ciabattoni G., et al. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) sequentially upregulates nitric oxide and prostanoid production in primary human endothelial cells. Circ Res 92 (2003) 732-740
17. Secchiero P., Corallini F., di Iasio M.G., Gonelli A., Barbarotto E., and Zauli G. TRAIL counteracts the proadhesive activity of inflammatory cytokines in endothelial cells by down-modulating CCL8 and CXCL10 chemokine expression and release. Blood 105 (2005) 3413-3419
18. Secchiero P., Candido R., Corallini F., Zacchigna S., Toffoli B., Rimondi E., et al. Systemic tumor necrosis factor-related apoptosis-inducing ligand delivery shows antiatherosclerotic activity in apolipoprotein E-null diabetic mice. Circulation 114 (2006) 1522-1530
19. Michowitz Y., Goldstein E., Roth A., Afek A., and Abashidze A. Ben Gal Y, Keren G, and George J. The involvement of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in atherosclerosis. J Am Coll Cardiol 45 (2005) 1018-1024
20. Schoppet M., Sattler A.M., Schaefer J.R., and Hofbauer L.C. Osteoprotegerin (OPG) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) levels in atherosclerosis. Atherosclerosis 184 (2006) 446-447
21. Jono S., Ikari Y., Shioi A., Mori K., Miki T., Hara K., et al. Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation 106 (2002) 1192-1194
22. Jin Z., Dicker D.T., and El-Deiry W.S. Enhanced sensitivity of G1 arrested human cancer cells suggests a novel therapeutic strategy using a combination of simvastatin and TRAIL. Cell Cycle 1 (2002) 82-89
23. Goke R., Goke A., Goke B., and Chen Y. Regulation of TRAIL-induced apoptosis by transcription factors. Cell Immunol 201 (2000) 77-82
24. Corallini F., Celeghini C., Rizzardi C., Pandolfi A., Di Silvestre S., Vaccarezza M., et al. Insulin down-regulates TRAIL expression in vascular smooth muscle cells both in vivo and in vitro. J Cell Physiol. 212 (2007) 89-95
25. Schoppet M., Sattler A.M., Schaefer J.R., Herzum M., Maisch B., and Hofbauer L.C. Increased osteoprotegerin serum levels in men with coronary artery disease. J Clin Endocrinol Metab 88 (2003) 1024-1028
26. Kiechl S., Schett G., Wenning G., Redlich K., Oberhollenzer M., Mayr A., et al. Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation 109 (2004) 2175-2180
27. Omland T., Ueland T., Jansson A.M., Persson A., Karlsson T., Smith C., et al. Circulating osteoprotegerin levels and long-term prognosis in patients with acute coronary syndromes. J Am Coll Cardiol 51 (2008) 627-633